finanzen.net
21.06.2019 09:00
Bewerten
(0)

DGAP-News: STADA Arzneimittel Aktiengesellschaft Announcement of the Results of the Tender Offer

DGAP-News: STADA Arzneimittel AG / Key word(s): Bond
STADA Arzneimittel Aktiengesellschaft Announcement of the Results of the Tender Offer

21.06.2019 / 09:00
The issuer is solely responsible for the content of this announcement.


NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO OR TO ANY PERSON LOCATED IN THE UNITED STATES.

June 21, 2019 - STADA Arzneimittel Aktiengesellschaft (the "Offeror") with its registered office at Stadastraße 2-18, 61118 Bad Vilbel, Federal Republic of Germany, hereby announces the results of its offer to purchase for cash (the "Tender Offer") any and all of its outstanding 1.750% Notes due 2022, issued on April 8, 2015 in an aggregate principal amount of EUR 300,000,000, ISIN XS1213831362, Common Code 121383136, WKN A14KJP (the "Notes") from holders of the Notes ("Noteholders"). The Tender Offer was made pursuant to the terms and conditions set out in the tender offer memorandum dated January 8, 2019 (the "Tender Offer Memorandum").

During the period from May 20, 2019, 3 pm CEST (the "Fifth Expiration Date") until June 19, 2019, 3 pm CEST (the "Final Expiration Date") Holders validly tendered Notes in an aggregate principal amount of EUR 3,040,000 for repurchase.

The Offeror hereby announces that it will accept all such Notes validly tendered as of the Final Expiration Date for repurchase under the terms and conditions set out in the Tender Offer Memorandum. The Final Payment Date (as defined in the Tender Offer Memorandum) is expected to be June 25, 2019.

Afterwards, Notes will still be outstanding in an aggregate principal amount of EUR 267,394,000.

The Tender Offer expired on the Final Expiration Date and no further repurchases will be made by the Offeror under this Tender Offer. In total, Notes in an aggregate principal amount of EUR 6,676,000 were repurchased under the Tender Offer since its announcement on January 8, 2019.

Requests for information in relation to the Tender Offer can be directed to the Tender Agent:

THE TENDER AGENT

Deutsche Bank Aktiengesellschaft
Taunusanlage 12
60325 Frankfurt am Main
Federal Republic of Germany

Attention: Trust and Agency Services
Telephone (UK): +44 20 7547 5000
Telephone (Germany): +49 69 910 35270
Email: xchange.offer@db.com

THE OFFEROR

STADA Arzneimittel Aktiengesellschaft
Stadastraße 2 - 18
61118 Bad Vilbel
Federal Republic of Germany

DISCLAIMER

NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO OR TO ANY PERSON LOCATED IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS) OR ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA.

The Tender Offer has not been made and will not be made, directly or indirectly, in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or of any facilities of a national securities exchange of, the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telephone and the internet. The Notes may not be tendered in the Tender Offer by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States. Accordingly, copies of this announcement, the Tender Offer Memorandum and any other documents or materials relating to the Tender Offer are not being, and must not be, directly or indirectly, mailed or otherwise transmitted, distributed or forwarded (including, without limitation, by custodians, nominees or trustees) in or into the United States or to any persons located or resident in the United States. Any purported tender of Notes in the Tender Offer resulting directly or indirectly from a violation of these restrictions will be invalid and any purported tender of Notes made by a person located or resident in the United States, or any agent, fiduciary or other Intermediary acting on a non-discretionary basis for a principal giving instructions from within the United States will be invalid and will not be accepted.

The distribution of the Tender Offer Memorandum in certain jurisdictions may be restricted by law. Persons into whose possession the Tender Offer Memorandum comes are required by the Offeror and the Tender Agent to inform themselves about, and to observe, any such restrictions.

This announcement is neither an offer to purchase nor the solicitation of an offer to sell any of the securities described herein, nor shall there be any offer or sale of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Tender Offer was made solely pursuant to the Tender Offer Memorandum dated January 8, 2019.

This announcement must be read in conjunction with the Tender Offer Memorandum. This announcement and the Tender Offer Memorandum contain important information which should be read carefully before any decision is made with respect to the Tender Offer. If any Holder is in any doubt as to the action it should take, it is recommended that such Holder seek its own financial and legal advice, including as to any tax consequences, immediately from its stockbroker, bank manager, solicitor, accountant or other independent financial or legal adviser. Any individual or company whose Notes are held on its behalf by a broker, dealer, bank, custodian, trust company or other nominee or intermediary must contact such entity if it wishes to tender Notes in the Tender Offer. None of the Offeror or the Tender Agent makes any recommendation as to whether Noteholders should participate in the Tender Offer.

Neither the information contained in this announcement nor any other documents or materials relating to the Tender Offer have been approved by, or will be submitted for approval to, the Luxembourg Financial Services Authority (Commission de Surveillance du Secteur Financier) for purposes of a public offering or sale in the Grand Duchy of Luxembourg ("Luxembourg"). Accordingly, the Tender Offer may not be made to the public in Luxembourg, directly or indirectly, and neither the Tender Offer Memorandum, nor any other offering circular, prospectus, form of application, advertisement or other material relating to the Tender Offer may be distributed, or otherwise made available in, from, or published in, Luxembourg except in circumstances which do not constitute an offer of securities to the public, subject to prospectus requirements, in accordance with the Luxembourg Act of July 10, 2005 on prospectuses for securities, as amended, and implementing the Prospectus Directive, as amended.

The Offer is not subject to the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetzes (WpÜG)). The offer document has not been submitted to the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin)) for inspection, review and/or approval. The Offer will also not be subject to notification, registration, approval or permission procedures outside of Germany nor have any such procedures been applied or induced for or been granted. The publication, dispatch, distribution or dissemination of the offer document and other documents related to the Offer outside the Federal Republic of Germany may be subject to legal restrictions. The offer document and other documents related to the Offer may not be dispatched to or disseminated, distributed or published by third parties in countries in which this would be illegal. Depositary Banks may not publish, dispatch, distribute, or disseminate the offer document outside the Federal Republic of Germany unless in compliance with all applicable domestic and foreign statutory provisions. The Offer will be made solely pursuant to the terms and conditions of the Offer as laid out in the offer document.

The information contained in this announcement have not been approved by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000. Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to those persons in the United Kingdom: (i) falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion Order")), (ii) falling within Article 43(2) of the Financial Promotion Order, including existing members and creditors of the Company; or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as "Relevant Persons"). Any person in the United Kingdom who is not a Relevant Person should not act or rely on this document or materials or any of their content.

This announcement contains forward-looking statements and information that are necessarily subject to risks, uncertainties, and assumptions. No assurance can be given that the transactions described herein will be consummated or as to the terms of any such transactions. The Offeror assumes no obligation to update or correct the information contained in this announcement.
 



21.06.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603-4689
Fax: +49 (0)6101 603- 215
E-mail: ir@stada.de
Internet: www.stada.de
ISIN: DE0007251803
WKN: 725180
Listed: Regulated Market in Dusseldorf; Regulated Unofficial Market in Hamburg, Munich
EQS News ID: 827965

 
End of News DGAP News Service

827965  21.06.2019 

fncls.ssp?fn=show_t_gif&application_id=827965&application_name=news&site_id=smarthouse

Nachrichten zu STADA

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu STADA

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
10.08.2018STADA SellS&P Capital IQ
09.05.2018STADA HaltenIndependent Research GmbH
08.05.2018STADA SellS&P Capital IQ
04.04.2018STADA SellWarburg Research
29.03.2018STADA HaltenIndependent Research GmbH
17.02.2017STADA Arzneimittel buyKepler Cheuvreux
13.02.2017STADA Arzneimittel buyKepler Cheuvreux
12.12.2016STADA Arzneimittel kaufenDZ BANK
29.11.2016STADA Arzneimittel buyKepler Cheuvreux
11.11.2016STADA Arzneimittel kaufenDZ BANK
09.05.2018STADA HaltenIndependent Research GmbH
29.03.2018STADA HaltenIndependent Research GmbH
21.03.2018STADA HaltenIndependent Research GmbH
12.03.2018STADA HaltenIndependent Research GmbH
20.12.2017STADA HaltenIndependent Research GmbH
10.08.2018STADA SellS&P Capital IQ
08.05.2018STADA SellS&P Capital IQ
04.04.2018STADA SellWarburg Research
23.03.2018STADA VerkaufenNorddeutsche Landesbank (Nord/LB)
12.03.2018STADA SellS&P Capital IQ

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für STADA nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX geht mit Abgaben ins Wochenende -- US-Börsen im Sinkflug -- Salesforce überraschend optimistisch -- thyssenkrupp will wohl KlöCo übernehmen -- Wirecard, Lufthansa im Fokus

HP bekommt neuen Chef. VW will sich womöglich an chinesischen Zulieferern beteiligen. Google ändert Android-Namensgebung. Commerzbank prüft wohl weiteren Abbau von bis zu 2500 Stellen. Continental will angeblich neun Werke schließen. Daimler hält an Kooperation mit Renault fest.

Die 5 beliebtesten Top-Rankings

Das hat sich geändert
Diese Aktien hat George Soros im Depot
Die 12 toten Topverdiener 2019
Diese Legenden sind die bestbezahlten Toten der Welt
Big-Mac-Index
In welchen Ländern kostet der Big Mac wie viel?
Das verdienen Aufsichtsratschefs in DAX-Konzernen
Deutlich unter Vorstandsgehältern
Die Länder mit den größten Goldreserven 2019
Wer lagert das meiste Gold?
mehr Top Rankings

Umfrage

Die Marktturbulenzen nehmen zu. Investieren Sie nun vermehrt in "sichere Häfen"?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Braas Monier Building Group S.A.BMSA01
MTU Aero Engines AG Em 2017A2G83P
Wirecard AG747206
Deutsche Bank AG514000
Daimler AG710000
CommerzbankCBK100
EVOTEC SE566480
BayerBAY001
Microsoft Corp.870747
Apple Inc.865985
Amazon906866
thyssenkrupp AG750000
NEL ASAA0B733
BASFBASF11
Klöckner & Co (KlöCo)KC0100